Real-world efficacy of anti-IL-5 treatment in patients with allergic bronchopulmonary aspergillosis

[1]  K. Asano,et al.  Treatments of refractory eosinophilic lung diseases with biologics. , 2022, Allergology international : official journal of the Japanese Society of Allergology.

[2]  M. Katsuno,et al.  A Review of Anti-IL-5 Therapies for Eosinophilic Granulomatosis with Polyangiitis , 2022, Advances in Therapy.

[3]  S. Muro,et al.  Successful management of recurrent allergic bronchopulmonary aspergillosis after changing from mepolizumab to dupilumab: A case report , 2022, Respiratory medicine case reports.

[4]  K. Asano,et al.  Eosinophilic Granulomatosis with Polyangiitis After Treatment with Dupilumab , 2022, Journal of Allergy and Clinical Immunology: Global.

[5]  M. Garg,et al.  A randomised trial of prednisolone versus prednisolone and itraconazole in acute-stage allergic bronchopulmonary aspergillosis complicating asthma , 2021, European Respiratory Journal.

[6]  E. Dunican,et al.  The Use of Targeted Monoclonal Antibodies in the Treatment of ABPA—A Case Series , 2021, Medicina.

[7]  R. Olivenstein,et al.  Eosinophilic pulmonary complications of dupilumab in two patients with asthma and chronic rhinosinusitis with nasal polyps. , 2021, The journal of allergy and clinical immunology. In practice.

[8]  M. M. van der Eerden,et al.  Reduced exacerbation frequency and prednisone dose in patients with ABPA and asthma treated with dupilumab , 2021, Clinical and translational allergy.

[9]  I. Pavord,et al.  Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study. , 2021, The Lancet. Respiratory medicine.

[10]  E. Gabazza,et al.  Complete withdrawal of glucocorticoids after dupilumab therapy in allergic bronchopulmonary aspergillosis: A case report , 2021, World journal of clinical cases.

[11]  K. Nakamoto,et al.  Successful Treatment of Mepolizumab- and Prednisolone-resistant Allergic Bronchopulmonary Aspergillosis with Dupilumab , 2021, Internal medicine.

[12]  K. Tsubouchi,et al.  A case of allergic bronchopulmonary aspergillosis with marked peripheral blood eosinophilia successfully treated with benralizumab , 2021, Respiratory medicine case reports.

[13]  A. Nanzer,et al.  Benralizumab after sub‐optimal response to mepolizumab in severe eosinophilic asthma , 2020, Allergy.

[14]  H. Matsuura,et al.  Successful Treatment with Benralizumab for Allergic Bronchopulmonary Aspergillosis That Developed after Disastrous Heavy Rainfall in Western Japan , 2020, Internal medicine.

[15]  K. Bergmann,et al.  Switch from IL-5 to IL-5-Receptor α Antibody Treatment in Severe Eosinophilic Asthma , 2020, Journal of asthma and allergy.

[16]  T. Shimoda,et al.  New Clinical Diagnostic Criteria for Allergic Bronchopulmonary Aspergillosis/Mycosis and its Validation. , 2020, The Journal of allergy and clinical immunology.

[17]  T. Baba,et al.  Effectiveness and Safety of Omalizumab in Patients with Allergic Bronchopulmonary Aspergillosis Complicated by Chronic Bacterial Infection in the Airways , 2020, International Archives of Allergy and Immunology.

[18]  L. Renaud,et al.  Mepolizumab for Allergic Bronchopulmonary Aspergillosis: report of 20 cases from the Belgian Severe Asthma Registry and review of the literature. , 2020, The journal of allergy and clinical immunology. In practice.

[19]  K. Asano,et al.  Rapid clearance of mepolizumab-resistant bronchial mucus plugs in allergic bronchopulmonary aspergillosis with benralizumab treatment. , 2020, Allergology international : official journal of the Japanese Society of Allergology.

[20]  F. Eun-Hyung Lee,et al.  Dupilumab treatment for Allergic Bronchopulmonary Aspergillosis: A case series. , 2019, The journal of allergy and clinical immunology. In practice.

[21]  M. Ardeleanu,et al.  Laboratory safety of dupilumab in moderate‐to‐severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS) , 2019, The British journal of dermatology.

[22]  C. Bachert,et al.  Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials , 2019, The Lancet.

[23]  M. To,et al.  Case series of allergic bronchopulmonary aspergillosis treated successfully and safely with long-term mepolizumab. , 2019, Allergology international : official journal of the Japanese Society of Allergology.

[24]  M. Nakazato,et al.  Successful treatment with mepolizumab in a case of allergic bronchopulmonary aspergillosis complicated with nontuberculous mycobacterial infection , 2019, Respiratory medicine case reports.

[25]  M. Garg,et al.  Allergic bronchopulmonary aspergillosis (ABPA) sans asthma: A distinct subset of ABPA with a lesser risk of exacerbation. , 2019, Medical mycology.

[26]  K. Asano,et al.  Allergic Bronchopulmonary Aspergillosis–A Luminal Hypereosinophilic Disease With Extracellular Trap Cell Death , 2018, Front. Immunol..

[27]  K. Asano,et al.  Allergic bronchopulmonary mycosis – pathophysiology, histology, diagnosis, and treatment , 2018, Asia Pacific allergy.

[28]  I. Pavord,et al.  Dupilumab Efficacy and Safety in Moderate‐to‐Severe Uncontrolled Asthma , 2018, The New England journal of medicine.

[29]  K. Kiura,et al.  Severe asthma concomitant with allergic bronchopulmonary aspergillosis successfully treated with mepolizumab. , 2018, Allergology International.

[30]  T. Terashima,et al.  A case of allergic bronchopulmonary aspergillosis successfully treated with mepolizumab , 2018, BMC Pulmonary Medicine.

[31]  M. Garg,et al.  A Randomized Trial of Itraconazole vs Prednisolone in Acute‐Stage Allergic Bronchopulmonary Aspergillosis Complicating Asthma , 2018, Chest.

[32]  E. Hoffman,et al.  Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction , 2018, The Journal of clinical investigation.

[33]  T. Shimoda,et al.  Allergic bronchopulmonary aspergillosis in Japan: A nationwide survey. , 2018, Allergology international : official journal of the Japanese Society of Allergology.

[34]  P. Le Pape,et al.  Azole Resistance in Aspergillus fumigatus in Patients with Cystic Fibrosis: A Matter of Concern? , 2017, Mycopathologia.

[35]  R. Segurado,et al.  Co-colonisation with Aspergillus fumigatus and Pseudomonas aeruginosa is associated with poorer health in cystic fibrosis patients: an Irish registry analysis , 2017, BMC Pulmonary Medicine.

[36]  J. Silverberg,et al.  Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. , 2016, The New England journal of medicine.

[37]  M. Adachi,et al.  Anti-IgE therapy for allergic bronchopulmonary aspergillosis. , 2016, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

[38]  J. Kelso.  Following total IgE concentration in patients with allergic bronchopulmonary aspergillosis on omalizumab. , 2016, The journal of allergy and clinical immunology. In practice.

[39]  A. Chakrabarti,et al.  Utility of IgE (total and Aspergillus fumigatus specific) in monitoring for response and exacerbations in allergic bronchopulmonary aspergillosis , 2016, Mycoses.

[40]  Yotaro Takaku,et al.  Pulmonary Nontuberculous Mycobacteriosis and Chronic Lower Respiratory Tract Infections in Patients with Allergic Bronchopulmonary Mycosis without Cystic Fibrosis. , 2016, Internal medicine.

[41]  Shiori Yamamoto,et al.  Eosinophil extracellular trap cell death-derived DNA traps: Their presence in secretions and functional attributes. , 2016, The Journal of allergy and clinical immunology.

[42]  R. O’Hehir,et al.  Clinical efficacy and immunologic effects of omalizumab in allergic bronchopulmonary aspergillosis. , 2015, The journal of allergy and clinical immunology. In practice.

[43]  M. Bălgrădean,et al.  Allergic bronchopulmonary aspergillosis in patient with cystic fibrosis - a case report. , 2014, Maedica.

[44]  R. Agarwal.  Burden and Distinctive Character of Allergic Bronchopulmonary Aspergillosis in India , 2014, Mycopathologia.

[45]  W. Busse,et al.  Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. , 2013, The Journal of allergy and clinical immunology.

[46]  D. Denning,et al.  Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria , 2013, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[47]  D. Cole,et al.  Global burden of allergic bronchopulmonary aspergillosis with asthma and its complication chronic pulmonary aspergillosis in adults. , 2013, Medical mycology.

[48]  Yotaro Takaku,et al.  Allergic bronchopulmonary aspergillosis with repeated isolation of nontuberculous mycobacteria. , 2013, Internal medicine.

[49]  Ó. Asensio,et al.  Effects of omalizumab in Aspergillus-associated airway disease , 2011, Thorax.

[50]  C. Peota.  Novel approach. , 2011, Minnesota medicine.

[51]  S. Sethi,et al.  Measured Immunoglobulin E in Allergic Bronchopulmonary Aspergillosis Treated With Omalizumab , 2010, The Journal of asthma : official journal of the Association for the Care of Asthma.

[52]  C. Mackay,et al.  MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. , 2010, The Journal of allergy and clinical immunology.

[53]  B. Preston,et al.  Case Series , 2010, Toxicologic pathology.

[54]  A. Chakrabarti,et al.  Clinical significance of decline in serum IgE levels in allergic bronchopulmonary aspergillosis. , 2010, Respiratory medicine.

[55]  S. Willsie.  Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma , 2010 .

[56]  E. Nussbaum,et al.  Resolution of Corticosteroid-Induced Diabetes in Allergic Bronchopulmonary Aspergillosis with Omalizumab Therapy: A Novel Approach , 2009, The Journal of asthma : official journal of the Association for the Care of Asthma.

[57]  A. Chakrabarti,et al.  Clinical significance of hyperattenuating mucoid impaction in allergic bronchopulmonary aspergillosis: an analysis of 155 patients. , 2007, Chest.

[58]  D. Behera,et al.  Allergic bronchopulmonary aspergillosis: lessons from 126 patients attending a chest clinic in north India. , 2006, Chest.

[59]  L BeSaw,et al.  A matter for concern , 1996, Texas medicine.

[60]  D. C. Henckel,et al.  Case report. , 1995, Journal.

[61]  R. Patterson,et al.  Allergic bronchopulmonary aspergillosis. Natural history and classification of early disease by serologic and roentgenographic studies. , 1986, Archives of internal medicine.

[62]  R. Patterson,et al.  Allergic bronchopulmonary aspergillosis: staging as an aid to management. , 1982, Annals of internal medicine.

[63]  Richard W. Willard.  The Nationwide Survey. , 1972 .